Carmat will resume implanting its artificial heart in October 2022 | Photo credits: Carmat
Jan 31 (Reuters) – French company Carmat said on Monday it could not resume implanting its Aeson artificial heart until next October.
The group had announced on December 2 the suspension of all implantations of Aeson, due to quality problems identified on some of its prostheses.
This decision was taken after three serious “adverse events”, including two deaths linked to malfunctions of the device, said Stéphane Piat, general manager, during a briefing.
“A rigorous investigation concluded that quality defects in two separate components of the prosthesis were the source of these issues,” the group said in a statement.
The new prostheses should be available by October 2022, Carmat said, adding that it has sufficient resources to finance its activities until July.
The title has lost nearly 30% since the announcement of the suspension and closed at 16.74 euros on Monday, against a price of 24.20 euros before the announcement. (Report Federica Mileo, edited by Tangi Salaün)